Price-to-earnings: BT vs RX

Over the past 12 months, mean P/Es for biotech and big pharma have trended down. The mean biotech P/E has fallen 15% to 13.3 from a year ago, while big pharma's multiple has fallen by 8% to 9.6. Biote...